Moriyasu Anai, Koichi Saruwatari, Kosuke Imamura, Kosuke Fujino, Takayuki Jodai, Shinya Sakata, Shinji Iyama, Yusuke Tomita, Sho Saeki, Hidenori Ichiyasu, Koei Ikeda, Makoto Suzuki, Takuro Sakagami
BACKGROUND: The clinical impact of tumor microvessels on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in EGFR mutation-positive non-small cell lung cancer (NSCLC) is unclear. Thus, the aim of this study was to investigate whether a tumor microenvironment, abundant in microvessels, affects EGFR-TKI efficacy in patients with NSCLC and EGFR mutations. METHODS: We retrospectively studied the data of 40 post-operative patients with recurrent NSCLC and EGFR mutations who received EGFR-TKIs as a first-line treatment at Kumamoto University Hospital from January 2010 to February 2021...
February 29, 2024: Journal of Thoracic Disease